Type B meeting – Talk Bio

Actionable Insights Powered by AI

MoonLake revives FDA push; biotech trio to debut in Hong Kong

4 days ago talkbio0Tagged * * Investor Day, Asia, Biological Factors, Blackfoot language, Capital, Hidradenitis Suppurativa, Hong Kong, HS drug approval pathway, immunotherapeutics, License Application, Market, MIRA trial, MoonLake, sonelokimab, Type B meeting, United States Food and Drug Administration, VELA-1 trial, VELA-2 trial

MoonLake Immunotherapeutics; Sonelokimab; Hidradenitis Suppurativa; FDA Type B meeting; Biologics License Application; BLA H2 2026; VELA-1 trial; VELA-2 trial; MIRA trial; HS drug approval pathway; investor day February 23 2026; Hong Kong biotech IPOs; Hong Kong listing; Asia biotech capital markets